Charles River Laboratories | CRL - Debt


Charles River Laboratories reported $3.06B in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Agilent USD 3.36B 1000K Mar/2026
Align Technology USD 116.04M 1.6M Mar/2026
Bio-Rad Laboratories USD 1.37B 7.8M Jun/2026
Bruker USD 1.82B 153.5M Jun/2026
Cardinal Health USD 8.89B 30M Jun/2026
Charles River Laboratories USD 3.06B 485.84M Mar/2026
Cigna USD 30.9B 563M Mar/2026
Concord Medical Services Hldg CNY 3.01B 27.15M Jun/2023
CVS Health USD 61.41B 16.94B Jun/2026
Danaher USD 26.56B 8.07B Jun/2026
Dentsply International USD 2.33B 137M Mar/2026
Elevance Health USD 31.04B 798M Jun/2026
Humana USD 14.25B 254M Jun/2026
Illumina USD 2.54B 9M Mar/2026
Incyte USD 38.27M 1.16M Jun/2026
Intrexon USD 0 13.82M Jun/2024
IQVIA Holdings USD 16.24B 408M Jun/2026
Laboratory Of America USD 7.24B 714.6M Mar/2026
Lakefront Biotherapeutics EUR 6.44M 480K Mar/2026
Lonza CHF 4.71B 915M Dec/2024
McKesson USD 8.61B 10M Mar/2026
Merck EUR 12.04B 86M Mar/2026
Mettler Toledo International USD 2.23B 76.47M Mar/2026
Novartis USD 49.01B 2.02B Jun/2026
Pfizer USD 63.19B 536M Jun/2026
Quest Diagnostics USD 6.41B 179M Mar/2026
Revvity USD 3.35B 48.03M Mar/2026
Thermo Fisher Scientific USD 43.16B 3.78B Mar/2026
United Therapeutics USD 200M 100M Mar/2025
UnitedHealth USD 73.33B 4.59B Jun/2026
Veradigm USD 200.33M 431K Sep/2022
Waters USD 5.57B 4.08B Mar/2026
West Pharmaceutical Services USD 202.8M 0 Mar/2026